Search - tctmd.com

Presenter: Israel M. Barbash, Rebecca Torgusson, Itsik Ben-Dor, Gabriel Maluenda, Zhenyi Xue, William O. Suddath, Lowell F. Satler, Kenneth M. Kent, Augusto D. Pichard, Ron Waksman

January 03, 2012

Presentation TCT 2012

Safety and Effectiveness of Everolimus-Eluting Stents in 5054 Patients from a Large, Prospective, Real World Study: Two-Year Clinical Outcomes from the XIENCE V® USA Study.

Presenter: Mitchell W. Krucoff, David R. Rutledge, Vivian W. Mao, Weiying Zhao, Alena V. Pechonkina, Jin Wang, Lalitha K. Jonnavithula, Krishnankutty Sudhir, James B. Hermiller

January 03, 2012

Presentation TCT 2012

Prospective Evaluation Of the Xience V Everolimus-Eluting Stent In Saphenous Vein Graft Atherosclerosis: the Xience V-SVG Angiographic Study.

Presenter: Emmanouil S. Brilakis, Aristotelis C. Papayannis, Abdul-rahman R. Abdel-karim, Tesfaldet T. Michael, Arif Mahmood, Lorenza B. Makke, Michele Roesle, Donald Haagen, Bavana V. Rangan, Subhash Banerjee

January 03, 2012

Presentation TCT 2012

Microarray Analysis for Nobori Biolimus A9 Eluting Stent and Xience V Everolimus Eluting Stent in Porcine Coronary Artery

Presenter: Arihiro Sumida, Selvamuthu Natarajan, Deepal Panchal, Jinsheng Li, Dongming Hou, Nicholas Chronos, Jaipal Singh, Surendra Chavan

January 03, 2012

Advertisement

Meta-Analysis: Cobalt-Chromium EES Cut Stent Thrombosis Compared with BMS, Other DES

La Evaluación de la FFR Contra la Enfermedad de los Vasos Pequeños Mejora los Resultados

FFR Assessment for Small Vessel Disease Improves Outcomes

Boston Scientific Announces New Clinical Data to be Presented at ACC 2012 on the Market-Leading PROMUS Element™ Stent

Abbott Reinforces Global Vascular Leadership with New Data on Innovative Technologies at ACC 2012

SES Effective for Both Focal, Diffuse DES Restenosis

El SLS es Efectivo contra la Reestenosis tanto Focal como Difusa del SLF

Stent Thrombosis Risk Lower with Xience vs. First-Generation DES

It’s DESTINY: DES Superior to BMS for Below-the-Knee Lesions

Ensayo DESTINY: los SLF son Superiores a los SMD en lesiones por debajo de la rodilla

El Riesgo de Trombosis del Stent es Menor con Xience que con SLF de 1ª Generación

Resolute Integrity: New Zotarolimus-Eluting Stent Gains FDA Approval

A Randomized Controlled Trial in Second-Generation Zotarolimus-Eluting Resolute vs. Everolimus-Eluting Xience V in Real-World Patients: TWENTE

NEXT Up: Polymer-Free SES Angiographically Superior to Taxus

SCAAR: Second-Generation DES Improve Hard Outcomes

The Impact of XIENCE V® Everolimus-Eluting Coronary Stents on Health Status in COURAGE-Like Patients.

Safety and Efficacy of the Xience Everolimus Eluting Stent Compared to First-Generation Drug-Eluting Stents in Contemporary Clinical Practice.

Safety and Effectiveness of Everolimus-Eluting Stents in 5054 Patients from a Large, Prospective, Real World Study: Two-Year Clinical Outcomes from the XIENCE V® USA Study.

Prospective Evaluation Of the Xience V Everolimus-Eluting Stent In Saphenous Vein Graft Atherosclerosis: the Xience V-SVG Angiographic Study.

Microarray Analysis for Nobori Biolimus A9 Eluting Stent and Xience V Everolimus Eluting Stent in Porcine Coronary Artery

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content